[Updated on Apr. 18] Integration of CiNii Articles into CiNii Research

Effect of a novel tachykinin NK-2-receptor antagonist, TAC-363, on bronchoconstriction and airway hyperresponsiveness in guinea pigs.

Bibliographic Information

Other Title
  • 新規タキキニンNK‐2受容体きっ抗薬,TAC‐363のモルモット気道収縮反応および気道過敏性に対する作用
  • 新規タキキニンNK-2受容体拮抗薬,TAC-363のモルモット気道収縮反応および気道過敏性に対する作用
  • シンキ タキキニン NK-2 ジュヨウタイ キッコウヤク TAC-363 ノ

Search this article

Abstract

We examined the effect of a novel tachykinin NK-2-receptor antagonist, Nα-(tert-Butylcarbamoyl)-L-glutaminyl-L-tryptophyl-α-aza-phenylalanine 2-benzyloxyethylamide (TAC-363), on hyperventilation- and citric acid-induced bronchoconstriction and neurokinin A (NKA)-, capsaicin- and antigen-induced airway hyperresponsiveness in guinea pigs. The i.v. administration of TAC-363 at doses of 0.01-1 mg/kg inhibited hyperventilation- and citric acid-induced bronchoconstriction in a dose-dependent manner, while FK-888, a tachykinin NK-1-receptor antagonist, did not inhibit hyperventilation-induced bronchoconstriction. NKA-induced airway hyperresponsiveness to acetylcholine was attenuated by i.v. injection of TAC-363, but not by the thromboxane A2 synthetase inhibitor ozagrel and the mast cell stabilizer DSCG. Furthermore, TAC-363 prevented the occurrence of capsaicin- and antigen-induced airway hyperresponsiveness to acetylcholine, while FK-888 did not prevent occurrence of capsaicin-induced airway hyperresponsiveness. In summary, TAC-363 inhibits bronchoconstriction and airway hyperresponsiveness induced by various stimuli. These results suggest that NKA mediates bronchoconstriction and airway hyperresponsiveness. Thus, TAC-363 is expected to be useful in the treatment of airway diseases such as asthma.

Journal

Citations (0)*help

See more

References(40)*help

See more

Related Articles

See more

Related Data

See more

Related Books

See more

Related Dissertations

See more

Related Projects

See more

Related Products

See more

Keywords

Details

Report a problem

Back to top